In fact, this approach is behind the motivation to pursue GluN2A-selective PAMs to treat the abovementioned disease or age-related declines in GluN2A's (expression and/or activity) (29, 78), and other diseases such as Dravet syndrome and AD (79). The gene discussed is GRIN2A; the disease is Dravet syndrome.